Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dalton, Oryn Therapeutics in Development, Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Dalton, Oryn Therapeutics in Development, Mfg. Pact

To provide cGMP aseptic liquid filling of Oryn’s RA drug in glass vials for Phase I trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dalton Pharma Services has signed a drug development and manufacturing services agreement with Oryn Therapeutics to provide drug development and cGMP aseptic liquid filling of Oryn’s ORTD-1 in glass vials for Phase I clinical studies.

ORTD-1 is a first-in-class drug for the treatment of rheumatoid arthritis (RA). ORTD-1 treatment of experimental arthritis in rats has been shown to induce remission of established disease after nine days of treatment, with remission lasting as long as 2-3 months after treatment is discontinued.

“Dalton is privileged to be associated with Oryn in its commitment to develop a safe and effective first-in-class drug treatment for RA,” said Peter Pekos, chief executive officer and president, Dalton Pharma Services.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics